antibody trastuzumab into the adjuvant treatment of women with HER2-positive breast tumors has been shown to reduce the risk of death and recurrence by almost 40% [4, 5] .
In parallel to the development of more efficacious therapeutic regimens has been a deeper understanding of the heterogeneity of breast cancer exemplified by the fact that we now recognize at least five different subtypes each with its own associated natural history [6] . We also recognize that inflammatory breast cancer (IBC) is a rare subtype of locally advanced breast cancer (LABC) characterized by a number of distinct features. First, IBC has a unique set of diagnostic criteria with the American Joint Committee on Cancer (AJCC) specifically classifying IBC as T4d and clinically defines it as 'a clinicopathologic entity characterized by diffuse erythema and edema of the breast, often without an underlying palpable mass' [7] . Secondly, IBC is known to have a worse prognostic outcome, a lower frequency of luminal A subtype, and a higher frequency of HER2-enriched subtype compared with non-IBC breast tumors [8, 9] .
There is no doubt that we have come a long way in the management of IBC. This is highlighted by the fact that before 1974 IBC was considered to be a uniformly fatal disease with a 5-year actuarial OS of <5% and a median survival of only 15 months [10] . With the introduction of a multidisciplinary management approach incorporating an anthracycline-based chemotherapy regimen and radiation therapy, this disease is now associated with 15-year survival rates of ∼20%-30% [11, 12] . We have previously shown that despite these advances, patients with IBC continue to have a poorer prognostic outcome compared with patients who have non-IBC [13] . The aim of this retrospective population-based study was to determine whether there has been a stepwise improvement in survival among women with stage III IBC over the last two decades reflecting the introduction of a number of efficacious therapeutic regimens that have been approved by the Food and Drug Administration (FDA).
patient and methods

patient population
We used data obtained from population registries participating in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry that covers ∼26% of the population in the United States [14] . We searched the18-SEER registries database released in April 2013. Search was restricted to female patients with stage III IBC, with a single primary, diagnosed between 1990 and 2010. SEER registry began collecting hormone receptor information in 1990, and we thus excluded patients who were diagnosed before 1990. In the most recent version, SEER provides an adjusted AJCC 6th edition stage criteria for patients diagnosed between 1988 and 2003 that is derived from the earlier extent of disease criteria and a derived AJCC 6th edition stage for cases diagnosed from 2004. For this study, IBC was defined according to the adjusted and derived AJCC 6th edition criteria. Follow-up cutoff was 31 December 2010. OS was calculated from the date of diagnosis to the date of death from any cause or the follow-up cutoff. Breast cancer-specific survival (BCSS) was calculated from the date of diagnosis to the date of death from breast cancer or the follow-up cutoff censoring patients who died from causes other than breast cancer. Survival outcomes were estimated using the Kaplan-Meier product limit method and compared across groups using the log-rank statistic. Specifically, the 2-year overall and BCSS rates for each individual year was estimated and plotted with 95% confidence intervals (CIs). A locally weighted least squares (LOWESS) [15] curve was fit to the individual year estimates without specifying a parametric model. In addition, we conducted a prespecified subset analyses stratified by year of diagnosis according to race, hormonal receptor status, and age group. A Bonferroni correction was used for multiple comparisons.
Cox proportional hazards models were fit to determine the association between year of diagnosis and survival outcomes after adjustment for patient characteristics. Variables included in the final model were based on clinical and statistical significance. Results were expressed in hazard ratios (HRs) and 95% CIs. P values <0.05 were considered statistically significant. All tests were two-sided. Statistical analyses were carried out using SAS 9.2(SAS Institute, Cary, NC) and S-Plus 7.0 (Insightful Corporation, Seattle, WA). 
results
patient characteristics
univariate analysis
Median follow-up among all patients was 30 months (range, 0-250 months). At the time of this analysis, 4616 patients (60%) had died from all causes and 3914 (51%) had died from breast cancer. Median BCSS and OS for the whole cohort was 50 and 42 months, respectively (supplementary Table S1 , available at Annals of Oncology online). OS and BCSS increased across the four time periods. The individual year 2-year OS and BCSS estimates, together with a LOWESS fit of the estimates, and the group year survival estimates, are presented in Figure 1 . Twoyear BCSS were 62%, 67%, 72%, and 76% for patients diagnosed between 1990-1995, 1996-2000, 2001-2005 , and 2006-2010, respectively (P < 0.0001). Table 2 summarizes unadjusted survival estimates stratified by year of diagnosis among predefined subgroups. OS and BCSS significantly increased across the four time periods regardless of race, hormone receptor status, and age ( 
multivariate analysis
In the multivariable model, increasing year of diagnosis was associated with a decreasing risk of death from breast cancer (HR = 0.98, 95% CI 0.97-0.99, P < 0.0001) ( Table 3) . Other factors significantly associated with an improved BCSS included negative nodes, being of white race, having hormone receptorpositive disease, and having lower grade of disease. Similar results were obtained for OS. 2010, a more than 22-month improvement in median BCSS and a 14% improvement in 2-year BCSS was observed. In the multivariable model, each increasing year of diagnosis from 1990 was associated with a decreasing risk of death from The results observed in our study are in contrast to prior retrospective studies that have attempted to answer a similar question. Gonzalez et al. [8] reported on a cohort of 398 women observed between our study and the ones reported previously may be attributed to a number of factors. First, the number of patients with IBC enrolled in the previous studies was so small that could make small differences in survival over time difficult to detect. Secondly, our analysis concentrated on patients diagnosed over the last two decades while in the prior studies the majority of patients were diagnosed in the 1980s and 1990s. Indeed, during the last decade, the FDA has approved a number of important agents for the treatment of breast cancer including aromatase inhibitors and trastuzumab. Thirdly, the majority of patients in the prior studies received anthracycline-based regimens with less than half of them receiving a taxane. Similar to patients with non-IBC, the addition of taxanes to an anthracycline-based chemotherapy regimen has also been shown to significantly improve survival among patients with IBC [17] . As illustrated in Figure 1 , the use of adjuvant paclitaxel was approved by the FDA in 1999 and although SEER does not document type of chemotherapy administered it is likely that most patients did receive it over the last decade and thus may account for one factor contributing to the significant improvement in survival observed in our study. Over the last decade, there have been significant advances in the understanding of IBC at the molecular level through efforts of organizations such as the World IBC consortium. This consortium recently reported on the molecular profile of IBC using the largest series of IBC samples [9] . The investigators reported on the affymetrix profiles from 137 patients with IBC and 252 patients with non-IBC, which were analyzed using unsupervised and supervised techniques, observing that the frequency of molecular subtypes were different with patients with IBC tumors exhibiting higher frequencies of HER2-enriched subtypes (22% versus 9%, P < 0.001) and lower frequency of luminal A subtype (19% versus 42%, P < 0.001) compared with patients with non-IBC. Several retrospective studies have reported that, in the absence of trastuzumab, HER2 status is not an independent adverse prognostic factor among patients with IBC, unlike that observed among patients with non-IBC [18, 19] . However, when trastuzumab is added to the treatment regimen of patients with HER2-positive IBC a significant improvement in prognostic outcome is observed similar to that seen for patients with HER2-positive non-IBC [18] . Gianni et al. [20] reported on a prospective phase III trial of 235 women with HER2-positive LABC of whom 63 had IBC who were randomized to receive either neoadjuvant chemotherapy alone or in combination with trastuzumab. The authors reported a significantly higher pCR rate (38% versus 19%) and 3-year event-free survival (71% versus 56%) among patients who received trastuzumab. In an updated analysis presented at the recent American Society of Clinical Oncology symposium, the authors reported a significant improvement in the 5-year event-free survival (57.5% versus 43.3%, P = 0.016) and 5-year BCSS (77.4% versus 63.9%, P = 0.023) favoring the group who received trastuzumab [21] . In summary, the results of our study show a significant stepwise improvement in survival over the last two decades among women with stage III IBC. The data presented suggest that therapeutic strategies researched and evolved in the context of non-IBC have also had a positive impact among women with IBC. We acknowledge that our study has a number of important limitations including the retrospective nature of the study design and the fact that SEER does not have information on HER2 status, type of chemotherapy administered or its sequence with locoregional treatment strategies. With IBC being a rare disease comprising of ∼1%-5% of all breast cancers, the large number of patients afforded by this population-based study is its main strength in allowing us to detect small differences in survival [23] . The improvement in survival observed may be attributed to the use of neoadjuvant regimens, aggressive locoregional treatment, improved diagnostic imaging for staging, as well as introduction of a number of important efficacious chemotherapeutic and biological agents over the last two decades [12, 21] . Data derived from SEER clearly demonstrates that, although IBC is rare, its incidence is rising [23] . Moreover, despite the demonstrated improvement in survival over time, the prognostic outcome of women with IBC continues to be poorer compared with those with non-IBC [13] . It is thus imperative that newer agents be developed and investigated specifically for IBC. Agents targeting VEGF (bevacizumab, semaxanib), HER2 (lapatinib, pertuzumab, afatinib), chemokine receptors (CXCR4 and CCR7), FAK1, ALK, and E-cadherin are currently being actively explored [24] . The way forward will be dictated by current collaborative efforts of organizations such as the world IBC consortium that are dedicated to a deeper understanding of the molecular biology of IBC and to the conduct of larger scale prospective multicenter clinical trials. 
